IL1R1 and congenital rubella syndrome: Tocilizumab, an anti-IL-6R mAb, and anakinra, an IL-1 receptor (IL-1R) agonist, are under investigation to reduce CRS-mediated toxicities in chimeric antigen receptor T-cell (CAR-T) therapy recipients (NCT04359784, NCT04150913) [171].